Clinical trials: ST Segment Elevation Acute Myocardial Infarction
- Condition ST Segment Elevation Acute Myocardial Infarction
- Funder type Industry (pharma, biotech, devices)
Acute Myocardial Infarction
Bivalirudin Infusion for Ventricular Infarction Limitation
The purpose of this study is to evaluate whether the use of bivalirudin will reduce extent of the damage done to the heart muscle in participants who suffered a heart attack, compared to the comparator treatment (heparin).
- Trial name
- BIVAL (NCT02565147)
- Testing
- PPCI, Bivalirudin, Heparin
- Where
- 4 sites in France, Netherlands
- Volunteers
- 78 people
- Sponsor
- The Medicines Company
STEMI - ST Elevation Myocardial Infarction, CAD
CorPath GRX STEMI Study
This study will evaluate the performance of the CorPath GRX System in Robotic Primary PCI (RPPCI) in the treatment of ST-elevated myocardial infarction (STEMI).
- Trial name
- TREAT GRX (NCT04459299)
- Testing
- Robotic-PCI (CorPath GRX System)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Siemens Healthineers Endovascular Robotics, Inc.
ST Segment Elevated Myocardial Infarction
OCT Study of the MGuard Prime Stent in Patients With Heart Attacks
The objective is to demonstrate that the Flow Area within a blocked coronary vessel as assessed by OCT is greater with the MGuard Prime stent compared to non-mesh control stent (BMS/DES) in subjects undergoing primary PCI for…
- Trial name
- MASTER-OCT (NCT02222116)
- Testing
- MGuard Prime, Control BMS DES
- Where
- United Kingdom
- Sponsor
- InspireMD
Myocardial Infarction
Bivalirudin in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary PCI
The purpose of this study is to demonstrate the benefit of bivalirudin in combination with clopidogrel with provisional GPIIb/IIIa inhibitor use, in reducing the bleeding complications associated with early invasive management of…
- Trial name
- NCT00093184
- Testing
- Angiomax (bivalirudin) anticoagulant
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- The Medicines Company
Coronary Artery Disease, Stable Angina
BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM
Prospective, multi-center, registry designed to enrol up to 2,000 patients in up to 35 International centers. All patients will receive a BioMatrix AlphaTM stent as per clinical practice and will be followed for 2 years for data…
- Conditions
- Coronary Artery Disease, Stable Angina, Ischemia, Acute Coronary Syndrome
- Trial name
- NCT02871622
- Testing
- BioMatrix AlphaTM
- Where
- United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Biosensors Europe SA
Myocardial Infarction, Cardiovascular Diseases
Safety and Efficacy Study of KAI-9803 to Treat Subjects With ST Elevation Myocardial Infarction [Heart Attack]
The purpose of this study is to determine whether KAI-9803 is safe and effective in reducing infarct size in subjects with ST elevation myocardial infarction (heart attack) undergoing a percutaneous coronary intervention (PCI).
- Conditions
- Myocardial Infarction, Cardiovascular Diseases, Pathologic Processes
- Trial name
- PROTECTION AMI (NCT00785954)
- Testing
- KAI-9803
- Where
- 126 sites in United States, Australia and 16 more
- Volunteers
- 1,180 people
- Sponsor
- KAI Pharmaceuticals
Coronary Stenosis, Acute Coronary Syndrome
Multiomics and Imaging-based Assessment of Vulnerable Coronary Plaques in Acute Coronary Syndromes
The aim of Multiplaque clinical study is to assess the vulnerability degree of the atheromatous plaques, before and after a myocardial infarction (MI), based on multiomics analysis, associated with invasive and non-invasive data.
- Conditions
- Coronary Stenosis, Acute Coronary Syndrome, Acute Myocardial Infarction, Atheromatous Plaques
- Trial name
- MultiPlaque (NCT03391908)
- Testing
- cardiac imaging tests
- Where
- Romania
- Volunteers
- 100 people
- Sponsor
- Cardio Med Medical Center
STEMI, Anterior MI
Pressure-controlled Intermittent Coronary Sinus Occlusion (PiCSO) in Acute Myocardial Infarction
The objective of this study is to assess efficacy and safety of Pressure-controlled intermittent Coronary Sinus Occlusion (PiCSO) therapy started post flow restoration but prior to stenting during percutaneous coronary…
- Trial name
- PiCSO-AMI-I (NCT03625869)
- Testing
- PiCSO
- Where
- 17 sites in Denmark, France and 4 more
- Volunteers
- 145 people
- Sponsor
- Miracor Medical SA
Acute Myocardial Infarction, ST Elevation MI
Nitric Oxide in Myocardial Infarction Size
The purpose of this study is to assess whether or not inhaled nitric oxide can decrease myocardial infarction (MI) size at 48-72 hours in patients presenting with an ST segment elevation MI (STEMI) who undergo successful…
- Conditions
- Acute Myocardial Infarction, ST Elevation MI, STEMI
- Trial name
- NOMI (NCT00568061)
- Testing
- Nitric Oxide
- Where
- 14 sites in United States, Belgium and 1 more
- Volunteers
- 29 people
- Sponsor
- Mallinckrodt
Unstable Angina, Coronary Atherosclerosis
Serp-1 for the Treatment of Acute Coronary Syndrome
Males and females aged 18-80 years who present with ACS (unstable angina and non ST-elevation MI) defined as one or more episodes of angina lasting at least 5 minutes in the last 24 hours before admission and greater than 0.05 mV…
- Conditions
- Unstable Angina, Coronary Atherosclerosis, Coronary Restenosis
- Trial name
- NCT00243308
- Testing
- Serine proteinase-1 (Serp-1)
- Where
- 8 sites in United States, Canada
- Volunteers
- 72 people
- Sponsor
- Viron Therapeutics Inc
Heart Attack, NSTEMI
A Phase 2 Trial of AMI MultiStem® Therapy in Subjects With Non-ST Elevation Acute Myocardial Infarction
This is a double-blind, sham-controlled clinical study to evaluate the safety and feasibility of AMI MultiStem therapy in subjects who have had a heart attack (Non-ST elevation MI).
- Trial name
- MI-NSTEMI (NCT02277613)
- Testing
- AMI MultiStem cells
- Where
- 11 sites in United States
- Volunteers
- 34 people
- Sponsor
- Healios K.K.
Acute Coronary Syndrome
A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
This is a randomized, double-blind, placebo-controlled, parallel group, multi-center study to evaluate initial safety and efficacy of GW856553 in subjects with NSTEMI.
- Trial name
- Solstice (NCT00910962)
- Testing
- GW856553
- Where
- 108 sites in United States, Australia and 7 more
- Volunteers
- 526 people
- Sponsor
- GlaxoSmithKline
Acute ST Segment Elevation Myocardial Infarction
ABSORB STEMI: the TROFI II Study
This is a Prospective, randomized (1:1), active control, single-blind, non-inferiority, European multicenter clinical trial. The primary objective of this study is to assess the neointimal healing score (as evaluated by…
- Trial name
- NCT01986803
- Testing
- Percutaneous Coronary Intervention
- Where
- 8 sites in Denmark, Netherlands and 2 more
- Volunteers
- 191 people
- Sponsor
- ECRI bv
Myocardial Infarction (MI), Acute Coronary Syndromes (ACS)
A Clinical Trial to Demonstrate the Efficacy of Cangrelor
The primary objective of this study is to demonstrate that the efficacy of cangrelor is superior, or at least non-inferior, to that of clopidogrel in subjects requiring PCI.
- Trial name
- PCI (NCT00305162)
- Testing
- Cangrelor (P2Y12 inhibitor), clopidogrel (oral P2Y12 inhibitor)
- Where
- United States
- Volunteers
- 8,882 people
- Sponsor
- The Medicines Company
STEMI
Door To Unloading With IMPELLA CP System in Acute Myocardial Infarction - Safety and Feasibility Study
Direct active unloading of the left ventricle with the Impella CP System prior to PPCI in patients with ST-elevation myocardial infarction (STEMI) is safe and feasible
- Trial name
- DTU (NCT03000270)
- Testing
- Impella unloading prior to PPCI
- Where
- 15 sites in United States
- Volunteers
- 50 people
- Sponsor
- Abiomed Inc.
Acute Coronary Syndromes
Investigation of the Biomarker Copeptin in Patients With Acute Myocardial Infarction
While troponin is not detectable until several hours after an Acute Myocardial Infarction (AMI), copeptin is expected to be elevated very early after an AMI.
- Trial name
- CHOPIN (NCT00952744)
- Where
- 11 sites in United States
- Volunteers
- 2,071 people
- Sponsor
- Brahms AG
Myocardial Infarction, Acute ST-Segment Elevation
Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction - Study 25 (ExTRACT-TIMI25)
The primary objective of the study is to determine whether enoxaparin compared to unfractionated heparin will reduce the composite endpoint of all-cause mortality and non-fatal myocardial re-infarction within 30 days after…
- Trial name
- NCT00077792
- Testing
- Enoxaparin sodium (XRP4563)
- Where
- 48 sites in United States, Argentina and 46 more
- Volunteers
- 20,506 people
- Sponsor
- Sanofi
Acute Non-ST Elevation Myocardial Infarction
DLBS1033 for Acute NSTEMI Without Early Coronary Revascularization
This is a prospective, randomized, double-blind, double-dummy, and controlled study of DLBS1033 in the management of acute non-ST elevation myocardial infarction (NSTEMI) without early coronary revascularization.
- Trial name
- NCT02146664
- Testing
- DLBS1033
- Where
- 2 sites in Indonesia
- Sponsor
- Dexa Medica Group
Acute Myocardial Infarction
Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction
This was a double-blind, randomized, placebo-controlled study that was designed to enroll a total of 225 participants with de novo anterior wall acute ST-segment elevation myocardial infarction (STEMI) due to a lesion of the left…
- Trial name
- AMICI (NCT01781390)
- Testing
- Mesenchymal Precursor Cells (MPC) 12.5 M, Mesenchymal Precursor Cells (MPC) 25 M
- Volunteers
- 106 people
- Sponsor
- Mesoblast, Inc.
Acute Coronary Syndrome (ACS)
Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)
This Phase IV, multicenter trial is designed to assess the efficacy of prasugrel in preventing the formation of blood clots in Taiwanese patients with ACS who have been treated with PCI.
- Trial name
- NCT03672097
- Testing
- Prasugrel
- Where
- 10 sites in Taiwan
- Volunteers
- 204 people
- Sponsor
- Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company